Key facts
- Marobio’s last known valuation is $26.8M (Feb 2026).
- It has raised $23.0M; the latest was Seed Round ($23.0M) in Feb 2026.
- Notable investors include Samsara BioCapital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Marobio
- ·The full record, as it builds
Funding rounds
No funding rounds for Marobio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Marobio
Developer of therapeutic agents designed for hematologic diseases. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Website
- marobio.com/
- Ownership
- Privately Held (backing)
Marobio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Marobio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Marobio in its N-PORT filings yet. We sweep new filings monthly.